Cerebrolysin is not a single molecule but a complex peptidergic preparation produced by standardized enzymatic breakdown of purified porcine brain proteins, yielding a mixture of low-molecular-weight peptides (reported under ~10 kDa) and free amino acids.1 It is studied as a putative neurotrophic agent. Because it is a defined-process biological mixture rather than a pure chemical entity, PubChem catalogues it only as substance records with no single compound CID, and a unique molecular formula, molar mass and InChIKey are not established.2 This monograph is provided for research and informational purposes only. Cerebrolysin is not an approved drug in the United States or Canada; it is marketed in some other jurisdictions but its regulatory status varies and is in places unclear.1 Nothing here is medical advice or a usage direction.
Sequence & identity
Mechanisms studied
Researchers have proposed that Cerebrolysin’s low-molecular-weight peptide fraction acts in a pleiotropic, neurotrophic-factor-like manner. A 2023 review in Medicinal Research Reviews reported that the preparation has been associated with simultaneous upregulation of brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), insulin-like growth factor-1 (IGF-1) and nerve growth factor (NGF), alongside downregulation of the inflammatory cytokine TNF-α.3 In that review and the preclinical literature it summarizes, investigators observed effects attributed to promotion of neurogenesis and synaptic plasticity, angiogenesis, anti-apoptotic and anti-inflammatory signaling, and modulation of amyloid-β and tau-related pathways in disease models.3 These mechanisms are described mainly at the preparation level; the specific active peptides and their individual targets remain incompletely characterized.
Dosing in the research literature
The figures below summarise regimens as reported in published research — they are not recommendations or directions for use.
| Source / model | Regimen reported | Notes |
|---|---|---|
| Gauthier 2015 — mild-to-moderate Alzheimer’s disease meta-analysis (6 RCTs) | 30 mL/day intravenous, administered in treatment courses, as reported across the pooled double-blind, placebo-controlled trials. | Reported in studies only — not a usage direction. Pooled cognitive standardized mean difference -0.40 (p=0.0031) at 4 weeks and improved global clinical change at 4 weeks and 6 months; authors reported safety comparable to placebo.4 |
| Guekht 2011 — vascular dementia RCT (n=242) | 20 mL/day intravenous as add-on to acetylsalicylic acid, given over two treatment cycles, as reported in the trial. | Study-reported only. ADAS-cog+ improved 10.6 vs 4.4 points (placebo) and CIBIC+ favored treatment, both p<0.0001 at week 24.5 |
| Vester 2021 — CAPTAIN moderate-to-severe TBI prospective meta-analysis (n=185) | 50 mL/day intravenous for 10 days, then two further cycles of 10 mL/day for 10 days, as add-on to usual care, as reported in the trials. | Study-reported only. Combined multidimensional outcome favored Cerebrolysin (Mann-Whitney 0.60; p=0.0156 at day 30; p=0.0146 at day 90; small-to-medium effect sizes).6 |
Effects observed in research
In mild-to-moderate Alzheimer’s disease, a meta-analysis of six randomized, placebo-controlled trials reported that Cerebrolysin was associated with improved cognition (standardized mean difference -0.40; p=0.0031) and favorable global clinical change, with an overall benefit-risk ratio the authors judged favorable.4 In vascular dementia, a 242-patient RCT observed greater improvement on ADAS-cog+ and CIBIC+ versus placebo (both p<0.0001).5 In moderate-to-severe traumatic brain injury, the pooled CAPTAIN trial series reported a statistically significant multidimensional outcome favoring Cerebrolysin at days 30 and 90, with small-to-medium effect sizes.6 Evidence in acute ischemic stroke is mixed: a 2025 meta-analysis of 14 RCTs (n=2,884) reported a modest but significant early NIHSS improvement (mean difference +1.39; 95% CI 0.53–2.25; p=0.020) and a comparable safety profile, while functional independence (mRS 0–2) showed only a non-significant trend (RR 1.31; 95% CI 0.90–1.91; p>0.05).7 A 2023 Cochrane review reached a more cautious conclusion, finding no evidence of benefit on all-cause death after acute ischemic stroke (RR 0.96; 95% CI 0.65–1.41) and reporting a possible increase in non-fatal serious adverse events (RR 2.39; 95% CI 1.10–5.23).1 These are research findings in clinical and preclinical models, not statements of benefit to any individual.
Strength of evidence
Grade B — limited and inconsistent human evidence. Multiple randomized, double-blind, placebo-controlled trials and meta-analyses exist across Alzheimer’s disease, vascular dementia, TBI and acute ischemic stroke, which places Cerebrolysin above purely preclinical agents.4567 However, the evidence base is genuinely mixed: stroke functional-independence and mortality endpoints have not been convincingly met, and a 2023 Cochrane review found no all-cause-death benefit and a possible excess of non-fatal serious adverse events.1 Many positive trials originate from a limited set of investigator groups and the manufacturer, and effect sizes are generally small-to-moderate. Because Cerebrolysin is a non-fully-characterized biological mixture, batch composition and the identity of active constituents are not fully defined, and pharmacokinetics are poorly characterized — a single-fragment half-life is not established (constituent peptide half-lives are reported to range from minutes upward).13 It is not approved by the FDA and is not an approved drug in Canada.1
Reconstitution & storage
Reconstitute with bacteriostatic water for laboratory handling. Store lyophilised material frozen and reconstituted material refrigerated. Use Peptigo’s reconstitution calculator and storage cheat sheet for working figures.
References
- Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews. 2023;(10):CD007026. doi:10.1002/14651858.CD007026.pub7 (found no evidence of benefit on all-cause death, RR 0.96 [95% CI 0.65-1.41], and a possible increase in non-fatal serious adverse events, RR 2.39 [95% CI 1.10-5.23]; certainty of evidence low to very low). See also Cerebrolysin regulatory status and composition overview: https://en.wikipedia.org/wiki/Cerebrolysin
- National Center for Biotechnology Information. PubChem substance records for the name ‘Cerebrolysin’ (12 SIDs; no single compound CID / InChIKey), confirming it is a registered substance mixture rather than a defined compound. PubChem PUG-REST, https://pubchem.ncbi.nlm.nih.gov/rest/pug/substance/name/Cerebrolysin/sids/JSON
- Rejdak K, Sienkiewicz-Jarosz H, Bienkowski P, Alvarez A. Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin. Medicinal Research Reviews. 2023;43(5):1668-1700. doi:10.1002/med.21960
- Gauthier S, Proaño JV, Jia J, Froelich L, Vester JC, Doppler E. Cerebrolysin in mild-to-moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015;39(5-6):332-347. doi:10.1159/000377672. PMID:25832905
- Guekht AB, Moessler H, Novak PH, Gusev EI; Cerebrolysin Investigators. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis. 2011;20(4):310-318. doi:10.1016/j.jstrokecerebrovasdis.2010.01.012. PMID:20656516
- Vester JC, Buzoianu AD, Florian SI, et al. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021;42(11):4531-4541. doi:10.1007/s10072-020-04974-6. PMID:33620612
- Patel PN, Mangal D, Patel K. Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials. Cureus. 2025;17(8):e91054. doi:10.7759/cureus.91054. PMID:41018475